Ethan Grant

Ethan Grant is currently the VP of Therapeutic Discovery at Immunai. Ethan has held this position since October 2021. Prior to this, they were the Senior Director at Gilead Sciences, Leader of a group of innovative scientists responsible for developing a pre-clinical pipeline of drugs to treat inflammatory diseases with a major focus on rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. Ethan Grant has been in the scientific field for over 25 years. Ethan started their career as a Research Fellow/Instructor at Brigham & Women's Hospital, Harvard Medical School from January 1995 to December 1999. Ethan then pursued their graduate studies at Harvard University from January 1989 to December 1995. After they obtained their degree, they became a Sr Scientist at Millennium Pharmaceuticals from January 2000 to December 2005. Ethan then moved on to SYNTA PHARMACEUTICALS where they were a Sr Scientist from January 2005 to December 2006. After that, they became the Sr Principal Scientist at Schering-Plough Research Institute from June 2006 to January 2010. Lastly, they were the Principal Scientist at MedImmune from January 2010 to October 2016. Throughout their career, Ethan Grant has made many contributions to the scientific community and has helped develop several important drugs that are used to treat various illnesses and diseases.

Ethan Grant received their Ph.D. in Immunology from Harvard University and their B.A. in Molecular/Cell Biology from Northwestern University's Integrated Science Program.

Ethan Grant works with Luis Voloch - Co-Founder & CTO, Evan Zisholtz - VP, Corporate Development, and Raviv Pryluk - SVP, Operations & Analytics. Their manager is Noam Solomon, Co-Founder & CEO.